H. Masur, M. Michelis, J. Greene, I. Onorato, and R. Stouwe, Pneumonia, New England Journal of Medicine, vol.305, issue.24, pp.1431-1439, 1981.
DOI : 10.1056/NEJM198112103052402

C. Flexner, HIV drug development: the next 25 years, Nature Reviews Drug Discovery, vol.42, issue.12, pp.959-66, 2007.
DOI : 10.1038/nrd2336

V. Simon and D. Ho, HIV/AIDS epidemiology, pathogenesis, prevention, and treatment, The Lancet, vol.368, issue.9534, pp.489-504, 2006.
DOI : 10.1016/S0140-6736(06)69157-5

S. Little, S. Holte, J. Routy, E. Daar, and M. Markowitz, Antiretroviral-Drug Resistance among Patients Recently Infected with HIV, New England Journal of Medicine, vol.347, issue.6, pp.385-94, 2002.
DOI : 10.1056/NEJMoa013552

A. Wensing and C. Boucher, Worldwide transmission of drug-resistant HIV, AIDS Rev, vol.5, issue.3, pp.140-55, 2003.

E. Daar and D. Richman, Confronting the Emergence of Drug-Resistant HIV Type 1: Impact of Antiretroviral Therapy on Individual and Population Resistance, AIDS Research and Human Retroviruses, vol.21, issue.5, pp.343-57, 2005.
DOI : 10.1089/aid.2005.21.343

D. Richman, D. Margolis, M. Dalaney, W. Greene, and D. Hazuda, The Challenge of Finding a Cure for HIV Infection, Science, vol.323, issue.5919, pp.1304-1311, 2009.
DOI : 10.1126/science.1165706

A. Carr and J. Amin, Efficacy and tolerability of initial antiretroviral therapy: a systematic review, AIDS, vol.23, issue.3, pp.343-53, 2009.
DOI : 10.1097/QAD.0b013e32831db232

S. Chiao, D. Romero, and D. Johnson, Current HIV therapeutics: mechanistic and chemical determinants of toxicity, Curr Opin Drug Discov Devel, vol.12, issue.1, pp.53-60, 2009.

M. Westby, G. Nakayama, S. Butler, and W. Blair, Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors, Antiviral Research, vol.67, issue.3, pp.121-161, 2005.
DOI : 10.1016/j.antiviral.2005.06.006

A. Boese, P. Sommer, A. Gaussin, A. Reimann, and U. Nehrbass, Ini1/hSNF5 is dispensable for retrovirus-induced cytoplasmic accumulation of PML and does not interfere with integration, FEBS Letters, vol.20, issue.3, pp.291-296, 2004.
DOI : 10.1016/j.febslet.2004.11.016
URL : https://hal.archives-ouvertes.fr/pasteur-00850261

P. Sommer, J. Vartanian, M. Wachsmuth, M. Henry, and D. Guetard, Anti-termination by SIV Tat Requires Flexibility of the Nascent TAR Structure, Journal of Molecular Biology, vol.344, issue.1, pp.11-28, 2004.
DOI : 10.1016/j.jmb.2004.09.042
URL : https://hal.archives-ouvertes.fr/pasteur-00850259

L. Reed and H. Muench, A simple method of estimating fifty percent endpoints, Am. J. Hyg, vol.27, pp.493-497, 1938.

J. Zhang, T. Chung, and K. Oldenburg, A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays, Journal of Biomolecular Screening, vol.4, issue.2, pp.67-73, 1999.
DOI : 10.1177/108705719900400206

C. Petropoulos, N. Parkin, K. Limoli, Y. Lie, and T. Wrin, A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1, Antimicrobial Agents and Chemotherapy, vol.44, issue.4, pp.920-928, 2000.
DOI : 10.1128/AAC.44.4.920-928.2000

H. Berman, Z. Westbrook, Z. Feng, G. Gilliland, and T. Bhat, The Protein Data Bank, Nucleic Acids Research, vol.28, issue.1, pp.235-242, 2000.
DOI : 10.1093/nar/28.1.235

D. Kertesz, C. Brontherton-pleiss, M. Yang, Z. Wang, and X. Lin, Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Benzyl derivatives with broad potency against resistant mutant viruses, Bioorganic & Medicinal Chemistry Letters, vol.20, issue.14, pp.4215-4218, 2010.
DOI : 10.1016/j.bmcl.2010.05.040

E. Lansdon, K. Brendza, M. Hung, R. Wang, and S. Mukund, Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design, Journal of Medicinal Chemistry, vol.53, issue.10, pp.53-4295, 2010.
DOI : 10.1021/jm1002233

T. Tucker, J. Sisko, R. Tynebor, T. Williams, and P. Felock, Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlor- ophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses, J. Med. Chem, issue.20, pp.51-6503, 2008.

L. Rosenblum, G. Patton, A. Grigg, A. Frater, and D. Cain, Differential Susceptibility of Retroviruses to Nucleoside Analogues, Antiviral Chemistry and Chemotherapy, vol.73, issue.2, pp.91-98, 2001.
DOI : 10.1177/095632020101200202

. Das-k, J. Bauman, A. Clark, Y. Frenkel, and P. Lewi, High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations, Proceedings of the National Academy of Sciences, vol.105, issue.5, pp.1466-71, 2008.
DOI : 10.1073/pnas.0711209105

D. Merrill, D. Manion, T. Chou, and M. Hirsch, Antagonism between Human Immunodeficiency Virus Type 1 Protease Inhibitors Indinavir and Saquinavir In Vitro, The Journal of Infectious Diseases, vol.176, issue.1, pp.265-273, 1997.
DOI : 10.1086/517263

J. Mcmahon, R. Gulakowski, O. Weislow, R. Schultz, and V. Narayanan, Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase., Antimicrobial Agents and Chemotherapy, vol.37, issue.4, pp.754-60, 1993.
DOI : 10.1128/AAC.37.4.754

N. Masuda, O. Yamamoto, M. Fujii, T. Ohgami, and J. Fujuyasu, Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides, Bioorganic & Medicinal Chemistry, vol.12, issue.23, pp.6171-82, 2004.
DOI : 10.1016/j.bmc.2004.08.050

N. Masuda, O. Yamamoto, M. Fujii, T. Ohgami, and J. Fujiyasu, Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure???activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives, Bioorganic & Medicinal Chemistry, vol.13, issue.4, pp.949-961, 2005.
DOI : 10.1016/j.bmc.2004.11.045